아토피 피부염(AD) : 역학 예측(-2033년)

Atopic dermatitis (AD) (International Classification of Diseases, 10th Revision [ICD-10] code L20) is a heterogenous and chronic inflammatory skin condition that is characterized by the remission and relapse of skin lesions and pruritus. Severe AD can impact patients' daily life and cause sleep disturbances, anxiety, depression, and impaired quality of life (QoL) (Kawaguchi et al., 2024; Silverberg et al., 2018).

AD is a complex disease that presents with a range of clinical manifestations and symptoms, depending on the patient demographic and disease severity (Nutten, 2015). The pathogenesis of AD is unclear, and most likely stems from the interaction of a combination of genetic susceptibility, environmental and lifestyle risk factors, and dysfunctional cell-mediated immunity. AD severity ranges from mild to severe. In severe cases, AD is associated with sleep disturbances due to the pruritic rashes that appear on the skin during a flare-up, depression and anxiety, and loss of productively, contributing to the economic and disease burden globally (Laughter et al., 2021). According to the Global Burden of Disease (GBD) database, AD ranks 15th among all nonfatal diseases and has the highest disease burden among skin diseases, as measured by disability-adjusted life-years (DALYs). A positive correlation has been found between a country's gross domestic product (GDP) and disease burden, and while the overall prevalence of AD has remained stable in the last decade, the age distribution of AD is a bimodal curve. The highest prevalence is seen in childhood, followed by the middle-age and older population (Laughter et al., 2021). However, prevalence variation exists depending on age, sex, ethnicity, and socio-economic status, and new epidemiological patterns are slowly emerging, such as AD prevalence increasing in low-income countries and new AD-onset in adults becoming increasingly more common, particularly in the West (Elsawi et al., 2022; Nutten, 2015).

Scope

• This report provides an overview of the severity and the global and historical epidemiological trends for AD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiology forecast for the 12-month diagnosed prevalent cases of AD. The 12-month diagnosed prevalent cases of AD are segmented by age (all ages) and sex (men and women). The 12-month diagnosed prevalent cases of AD among men and women are segmented by the severity of disease (mild, moderate, and severe).
• This epidemiology forecast for AD is supported by data obtained from country-specific peer-reviewed articles and population-based studies.
• The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast 12-month diagnosed prevalent cases of AD across these markets.

Reasons to Buy

• Atopic Dermatitis Epidemiology series will allow you to -
• - Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis markets.
• - Quantify patient populations in the global atopic dermatitis markets to improve product design, pricing, and launch plans.
• - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for atopic dermatitis therapeutics in each of the markets covered.
• - Understand magnitude of the atopic dermatitis population by age, sex, and disease severity.

Table of Contents

Table of Contents

• About GlobalData

1 Atopic Dermatitis: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumption and methods: 12-month diagnosed prevalent cases of AD
  • 2.4.4 Forecast assumptions and methods: 12-month diagnosed prevalent cases of AD by severity
• 2.5 Epidemiological forecast for AD (2023-33)
  • 2.5.1 12-month diagnosed prevalent cases of AD
  • 2.5.2 Age-specific 12-month diagnosed prevalent cases of AD
  • 2.5.3 Sex-specific 12-month diagnosed prevalent cases of AD
  • 2.5.4 12-month diagnosed prevalent cases of AD by severity
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
• Contact Us